Xinhua Pharmaceutical held a summary meeting of the Phase III clinical study of Ibuprofen injection in Beijing.

On January 29th, Xinhua Pharmaceuticals held a summary meeting on the "Randomized, double-blind, placebo-controlled, multicenter clinical study of the effectiveness and safety of ibuprofen injection in the treatment of postoperative moderate to severe pain." The research results showed that the ibuprofen injection developed by Xinhua Pharmaceuticals could significantly reduce the amount of morphine used postoperatively, effectively relieve the moderate to severe pain of postoperative patients. Its efficacy is better than placebo and it has good safety. It is expected to provide a new treatment option for clinical postoperative moderate to severe pain and support the clinical application of ibuprofen injection in the population with postoperative moderate to severe pain.